145 related articles for article (PubMed ID: 36712053)
1. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.
Nyman J; Denize T; Bakouny Z; Labaki C; Titchen BM; Bi K; Hari SN; Rosenthal J; Mehta N; Jiang B; Sharma B; Felt K; Umeton R; Braun DA; Rodig S; Choueiri TK; Signoretti S; Van Allen EM
bioRxiv; 2023 Feb; ():. PubMed ID: 36712053
[TBL] [Abstract][Full Text] [Related]
2. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.
Nyman J; Denize T; Bakouny Z; Labaki C; Titchen BM; Bi K; Hari SN; Rosenthal J; Mehta N; Jiang B; Sharma B; Felt K; Umeton R; Braun DA; Rodig S; Choueiri TK; Signoretti S; Van Allen EM
Cell Rep Med; 2023 Sep; 4(9):101189. PubMed ID: 37729872
[TBL] [Abstract][Full Text] [Related]
3. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.
Stenzel PJ; Schindeldecker M; Tagscherer KE; Foersch S; Herpel E; Hohenfellner M; Hatiboglu G; Alt J; Thomas C; Haferkamp A; Roth W; Macher-Goeppinger S
Transl Oncol; 2020 Feb; 13(2):336-345. PubMed ID: 31881506
[TBL] [Abstract][Full Text] [Related]
5. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
6. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
[TBL] [Abstract][Full Text] [Related]
7. Deep learning-based predictions of clear and eosinophilic phenotypes in clear cell renal cell carcinoma.
Ohe C; Yoshida T; Amin MB; Uno R; Atsumi N; Yasukochi Y; Ikeda J; Nakamoto T; Noda Y; Kinoshita H; Tsuta K; Higasa K
Hum Pathol; 2023 Jan; 131():68-78. PubMed ID: 36372298
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
[TBL] [Abstract][Full Text] [Related]
10. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
11. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study.
Al-Danakh A; Safi M; Alradhi M; Chen Q; Baldi S; Zhu X; Yang D
Cells; 2022 Nov; 11(22):. PubMed ID: 36429070
[No Abstract] [Full Text] [Related]
13. High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints.
Raghubar AM; Matigian NA; Crawford J; Francis L; Ellis R; Healy HG; Kassianos AJ; Ng MSY; Roberts MJ; Wood S; Mallett AJ
NPJ Precis Oncol; 2023 Sep; 7(1):88. PubMed ID: 37696903
[TBL] [Abstract][Full Text] [Related]
14. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
[TBL] [Abstract][Full Text] [Related]
17. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
18. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
[No Abstract] [Full Text] [Related]
19. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
